Ayad Yousif1, Caleb Natale1, Wayne J G Hellstrom2. 1. Department of Urology, Tulane University School of Medicine, 1430 Tulane Ave. 86-42, New Orleans, LA, 70112, USA. 2. Department of Urology, Tulane University School of Medicine, 1430 Tulane Ave. 86-42, New Orleans, LA, 70112, USA. whellst@tulane.edu.
Abstract
PURPOSE OF REVIEW: To analyze the literature on current conservative treatment options for Peyronie's disease (PD). RECENT FINDINGS: Conservative therapy with intralesional collagenase clostridium histolyticum (CCH) is safe and efficacious in either the acute or chronic phases of PD. Combination treatment with penile traction therapy (PTT) can produce even better results. While most PTT devices require extended periods of therapy up to 8 h per day, the RestoreX® device can be effective at 30-90 min per day. A variety of conservative therapies are available for treatment of PD. The available literature does not reveal any treatment benefit of oral therapies. Intralesional therapy is the mainstay conservative treatment of PD. Intralesional CCH therapy is the first Food and Drug Administration-approved intralesional therapy and represents the authors' preference for medical therapy. The most effective conservative management of PD likely requires a combination of therapies.
PURPOSE OF REVIEW: To analyze the literature on current conservative treatment options for Peyronie's disease (PD). RECENT FINDINGS: Conservative therapy with intralesional collagenase clostridium histolyticum (CCH) is safe and efficacious in either the acute or chronic phases of PD. Combination treatment with penile traction therapy (PTT) can produce even better results. While most PTT devices require extended periods of therapy up to 8 h per day, the RestoreX® device can be effective at 30-90 min per day. A variety of conservative therapies are available for treatment of PD. The available literature does not reveal any treatment benefit of oral therapies. Intralesional therapy is the mainstay conservative treatment of PD. Intralesional CCH therapy is the first Food and Drug Administration-approved intralesional therapy and represents the authors' preference for medical therapy. The most effective conservative management of PD likely requires a combination of therapies.
Authors: Scott C Brimley; Faysal A Yafi; Jacob Greenberg; Wayne J G Hellstrom; Hoang Minh Tue Nguyen; Georgios Hatzichristodoulou Journal: Sex Med Rev Date: 2018-11-30
Authors: Ajay Nehra; Ralph Alterowitz; Daniel J Culkin; Martha M Faraday; Lawrence S Hakim; Joel J Heidelbaugh; Mohit Khera; Erin Kirkby; Kevin T McVary; Martin M Miner; Christian J Nelson; Hossein Sadeghi-Nejad; Allen D Seftel; Alan W Shindel; Arthur L Burnett Journal: J Urol Date: 2015-06-09 Impact factor: 7.450
Authors: Eric Chung; David Ralph; Ates Kagioglu; Guilio Garaffa; Ahmed Shamsodini; Trinity Bivalacqua; Sidney Glina; Lawrence Hakim; Hossein Sadeghi-Nejad; Gregory Broderick Journal: J Sex Med Date: 2016-06 Impact factor: 3.802